Rugo HS - Search Results

1

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Dickler MN, et al. Among authors: rugo hs. J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2. J Clin Oncol. 2016. PMID: 27138575 Free PMC article. Clinical Trial.

2

High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.

Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. Smith GA, et al. Among authors: rugo hs. J Clin Oncol. 1997 Feb;15(2):833-9. doi: 10.1200/JCO.1997.15.2.833. J Clin Oncol. 1997. PMID: 9053511

3

Bevacizumab in the treatment of breast cancer: rationale and current data.

Rugo HS. Rugo HS. Oncologist. 2004;9 Suppl 1:43-9. doi: 10.1634/theoncologist.9-suppl_1-43. Oncologist. 2004. PMID: 15178815 Free article. Review.

4

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Miller KD, et al. Among authors: rugo hs. J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098. J Clin Oncol. 2005. PMID: 15681523 Clinical Trial.

5

High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.

Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. Chaudhary UB, et al. Among authors: rugo hs. Am J Clin Oncol. 2005 Apr;28(2):130-7. doi: 10.1097/01.coc.0000144264.00518.47. Am J Clin Oncol. 2005. PMID: 15803005 Clinical Trial.

6

MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. Partridge SC, et al. Among authors: rugo hs. AJR Am J Roentgenol. 2005 Jun;184(6):1774-81. doi: 10.2214/ajr.184.6.01841774. AJR Am J Roentgenol. 2005. PMID: 15908529

7

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Rugo HS, et al. J Clin Oncol. 2005 Aug 20;23(24):5474-83. doi: 10.1200/JCO.2005.04.192. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027439 Clinical Trial.

8

The role of angiogenesis inhibition in the treatment of breast cancer.

Sledge GW Jr, Rugo HS, Burstein HJ. Sledge GW Jr, et al. Among authors: rugo hs. Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2006. PMID: 17139244 Review.

9

Hormonal therapy for advanced breast cancer.

Rugo HS. Rugo HS. Hematol Oncol Clin North Am. 2007 Apr;21(2):273-91. doi: 10.1016/j.hoc.2007.03.007. Hematol Oncol Clin North Am. 2007. PMID: 17512449 Review.

10

Bevacizumab for advanced breast cancer.

Traina TA, Rugo HS, Dickler M. Traina TA, et al. Among authors: rugo hs. Hematol Oncol Clin North Am. 2007 Apr;21(2):303-19. doi: 10.1016/j.hoc.2007.03.006. Hematol Oncol Clin North Am. 2007. PMID: 17512451 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

500 results

Search Page